Spectrum jumps following FDA approval of Rolvedon injection Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Bill.com (BILL) up 3% after Morgan Stanley analyst Keith Weiss initiated coverage of Bill.com with an Overweight rating and $220 price target
- Spectrum (SPPI) up 16% after announcing that the FDA has approved Rolvedon injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
- AstraZeneca (AZN) up 1% after announcing updated results from the TOPAZ-1 Phase III trial showed its Imfinzi, in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival benefit as a treatment for patients with advanced biliary tract cancer
- Bristol-Myers (BMY) up 7% after announcing new two-year results from the POETYK PSO long-term extension trial demonstrating clinical efficacy was maintained with continuous Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis
- Ventyx Biosciences (VTYX) up 52% following the FDA approval of Bristol-Myers' Sotyktu, or deucravacitinib, with analysts highlighting the clean label for the drug as one that sets a favorable precedent for the TYK2i class
- XL Fleet (XL) up 2% after announcing the completion of its Spruce Power acquisition and that the company intends to appoint Christian Fong as CEO on or prior to February 15, 2023
UP AFTER EARNINGS -
LOWER -
- Relay Therapeutics (RLAY) down 1% after offering to sell $300M in common stock
- Roblox (RBLX) down 1% after Cowen analyst Doug Creutz initiated coverage of shares with an Underperform rating and $31 price target
- Twitter (TWTR) down 1% after Tesla CEO Elon Musk claimed that Twitter's severance payments to Zatko and his counsel totaling $7.75M is another basis to terminate Musk's deal to buy Twitter
- Adobe (ADBE) down 1% after Mizuho analyst Gregg Moskowitz downgraded the stock to Neutral ahead of the company's fiscal Q3 report due on September 15
Symbols:
BILL SPPI AZN BMY XL AKTS RLAY RBLX TWTR ADBE - $394.68 /
+11.08 (+2.89%)
VTYX Keywords: Fly Intel, Wall Street, Top Stories, Stocks